$VSTM

Novocure (NVCR) and Verastem Oncology plan a clinical trial to evaluate Tumor Treating Fields (TTFields) therapy with chemotherapy and Verastem’s experimental drug VS-7375 for locally advanced pancreatic cancer. The trial, expected to start in 2027, will assess safety and preliminary efficacy in about 25 patients. Novocure will manage and fund the trial, while Verastem will supply the drug. Both companies believe the combination could offer a new treatment approach for this challenging cancer.

Verastem Oncology (VSTM) will release Q3 2026 financial results and business updates on Nov 5, 2026. The company will host a conference call and webcast, available on its investor relations website. Verastem focuses on developing treatments for RAS/MAPK pathway-driven cancers and markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S.

Verastem Inc (VSTM) received a 'Buy' rating and $24.00 price target from BTIG. The biotech company focuses on cancer therapies, with a market cap of $785.18M. Analysts are optimistic, but the stock has a low GF Score™ (23/100) and high P/S ratio (19.82x). Insider activity shows recent selling.

H.C. Wainwright reiterated a Buy rating and $18.00 price target for Verastem (VSTM) after positive clinical trial data from China. The stock rose 10% last week to $9.23, up 46% in six months. GenFleet's data showed promising results for GFH375, the same molecule as Verastem's VS-7375, in colorectal and pancreatic cancer trials. Analysts maintain a strong buy consensus with targets ranging from $12 to $24.

Verastem's KRAS inhibitor, VS-7375, showed a 75% ORR in lung cancer trials. The company plans FDA meetings and further trials. Competitors like MSD, Lilly, and Roche are also developing KRAS-targeting drugs. More data is expected by year-end 2026.

Mizuho raised its price target on Verastem Inc. (VSTM) to $14 from $13, citing strong clinical trial data for its oral KRAS G12D inhibitor. The stock trades at $7.71, with analysts' targets ranging from $12 to $24. Verastem plans a Phase 3 study and completed a $250 million financing. Multiple analysts maintain positive ratings, with price targets up to $19.

BTIG maintained a Buy rating on Verastem with a $24 price target, implying a 211.3% upside. Analysts cited strong clinical efficacy of VS-7375, including a 41% cORR and 67% six-month PFS, and a favorable safety profile.

RBC Capital raised its price target for Verastem Inc. (VSTM) to $19.00 from $14.00, citing positive data for its G12D drug candidate. The firm maintains an Outperform rating, noting potential market share and undervaluation. Verastem's Q2 2026 earnings showed a 34% revenue increase, surpassing estimates. Analysts have mixed price targets but generally positive ratings.

Verastem, Inc. (VSTM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 14, 2026, Verastem, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named in Schedule I thereto (the “Un

Verastem (VSTM) reported positive results for its KRAS G12D drug in pancreatic, colorectal, and lung cancer trials. Key data includes a 43% response rate in lung cancer and 75% in frontline lung cancer combinations. The FDA agreed to the Phase III pancreatic cancer study design. The company expects to complete Phase II enrollments by year-end and has secured financing to fund operations into 2028.